ConductScience.org, home

Paper42972012PubMed

The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma.

Farag OB and 25 others. Leukemia, 2026.

Cite this record

ConductScience Library. The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma. Papers, record 42972012. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42972012

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma.
Journal
Leukemia
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-11-02

Source PubMed

Authors26

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Farag OBOlivia Bhttps://orcid.org/0009-0002-5457-5056
2Awada BBassel
3Youssfi AAAbdessamad A
4Manara PPaola
5Kingham AAnna
6Kumar PPreet
7Li LLingxiao
8Silver BBBrian B
9Shastri TToral
10Vilar SSantiago
11Newsam ADAustin D
12Lekakis MMarianna
13Hernandez Parets DEDiego Ehttps://orcid.org/0009-0006-9017-1998
14Younes PAPierre A
15Chahar DDhanvantri
16Arumov AArtavazd
17Coughlin CACaroline A
18Bilbao-Martinez AAlicia
19Gokara MMahesh
20Maura FFrancescohttps://orcid.org/0000-0002-5017-1620

Source PubMed

See all 26 authorsDownload CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants32

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01CA296318U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)R01CA296318PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
R01CA296318U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)R01CA296318PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
R01CA296318U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)R01CA296318PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
R01CA296318U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)R01CA296318PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
R01CA296318U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)R01CA296318PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
R01CA296318U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)R01CA296318PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER
P30CA240139U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)P30CA240139PubMedNIH RePORTER

See all 32 grantsDownload CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
141233615FDA approves 100th small-molecule kinase inhibitor.Nat Rev Drug Discov2025https://conductscience.org/library/papers/41233615PubMed
231819260The functional landscape of the human phosphoproteome.Nat Biotechnol2020https://conductscience.org/library/papers/31819260PubMed
33044542715 years of PhosphoSitePlus®: integrating post-translationally modified sites, disease variants and isoforms.Nucleic Acids Res2019https://conductscience.org/library/papers/30445427PubMed
436631611An atlas of substrate specificities for the human serine/threonine kinome.Nature2023https://conductscience.org/library/papers/36631611PubMed
538720073The intrinsic substrate specificity of the human tyrosine kinome.Nature2024https://conductscience.org/library/papers/38720073PubMed
6276185632016 US lymphoid malignancy statistics by World Health Organization subtypes.CA Cancer J Clin2016https://conductscience.org/library/papers/27618563PubMed
710676951Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.Nature2000https://conductscience.org/library/papers/10676951PubMed
819038878Stromal gene signatures in large-B-cell lymphomas.N Engl J Med2008https://conductscience.org/library/papers/19038878PubMed
932289277A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.Cancer Cell2020https://conductscience.org/library/papers/32289277PubMed
1026314773Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2015https://conductscience.org/library/papers/26314773PubMed
1140991874Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.J Clin Oncol2025https://conductscience.org/library/papers/40991874PubMed
1233657296Diffuse Large B-Cell Lymphoma.N Engl J Med2021https://conductscience.org/library/papers/33657296PubMed
1335933930Treatment strategies for patients with diffuse large B-cell lymphoma.Cancer Treat Rev2022https://conductscience.org/library/papers/35933930PubMed
1437879047Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).Blood2024https://conductscience.org/library/papers/37879047PubMed
1530901302Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.J Clin Oncol2019https://conductscience.org/library/papers/30901302PubMed
1638899693Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.N Engl J Med2024https://conductscience.org/library/papers/38899693PubMed
1723813874Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.Am J Hematol2013https://conductscience.org/library/papers/23813874PubMed
1816895969Recruitment dynamics of GAK and auxilin to clathrin-coated pits during endocytosis.J Cell Sci2006https://conductscience.org/library/papers/16895969PubMed
1919654208GAK, a regulator of clathrin-mediated membrane traffic, also controls centrosome integrity and chromosome congression.J Cell Sci2009https://conductscience.org/library/papers/19654208PubMed
2031962345Dynamics of Auxilin 1 and GAK in clathrin-mediated traffic.J Cell Biol2020https://conductscience.org/library/papers/31962345PubMed

See all 49 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42972012

GET https://conductscience.org/api/papers/v1/42972012/authors?page=2